Mark E. Bunnage - 01 Feb 2026 Form 3 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Scientific Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2026
Net transactions value
$0
Form type
3
Filing time
03 Feb 2026, 16:09:29 UTC
Next filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bunnage Mark E. EVP, Chief Scientific Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 03 Feb 2026 0002100735

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VRTX Common Stock 16,062 01 Feb 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Exhibit 24 - Power of Attorney